These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
387 related articles for article (PubMed ID: 34176768)
1. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. Bravi CA; Droghetti M; Fossati N; Gandaglia G; Suardi N; Mazzone E; Cucchiara V; Scuderi S; Barletta F; Schiavina R; Osmonov D; Juenemann KP; Boeri L; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A Eur Urol Oncol; 2022 Jun; 5(3):285-295. PubMed ID: 34176768 [TBL] [Abstract][Full Text] [Related]
2. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A Eur Urol; 2020 Nov; 78(5):661-669. PubMed ID: 32624288 [TBL] [Abstract][Full Text] [Related]
3. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients. Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093 [TBL] [Abstract][Full Text] [Related]
4. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. Fossati N; Suardi N; Gandaglia G; Bravi CA; Soligo M; Karnes RJ; Shariat S; Battaglia A; Everaerts W; Joniau S; Van Poppel H; Rajarubendra N; Gill IS; Larcher A; Mottrie A; Schmautz M; Heidenreich A; Kalz A; Osmonov D; Juenemann KP; Herlemann A; Gratzke C; Stief C; Montorsi F; Briganti A Eur Urol; 2019 Jan; 75(1):176-183. PubMed ID: 30301694 [TBL] [Abstract][Full Text] [Related]
5. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. Gandaglia G; Boorjian SA; Parker WP; Zaffuto E; Fossati N; Bandini M; Dell'Oglio P; Suardi N; Montorsi F; Karnes RJ; Briganti A Eur Urol; 2017 Dec; 72(6):910-917. PubMed ID: 28622831 [TBL] [Abstract][Full Text] [Related]
6. Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Suardi N; Gandaglia G; Gallina A; Di Trapani E; Scattoni V; Vizziello D; Cucchiara V; Bertini R; Colombo R; Picchio M; Giovacchini G; Montorsi F; Briganti A Eur Urol; 2015 Feb; 67(2):299-309. PubMed ID: 24571959 [TBL] [Abstract][Full Text] [Related]
7. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. Bravi CA; Fossati N; Gandaglia G; Suardi N; Mazzone E; Robesti D; Osmonov D; Juenemann KP; Boeri L; Jeffrey Karnes R; Kretschmer A; Buchner A; Stief C; Hiester A; Nini A; Albers P; Devos G; Joniau S; Van Poppel H; Shariat SF; Heidenreich A; Pfister D; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A Eur Urol; 2020 Dec; 78(6):779-782. PubMed ID: 32624281 [TBL] [Abstract][Full Text] [Related]
8. Oligorecurrent prostate cancer treated with metastases-directed therapy or standard of care: a single-center experience. Boeri L; Sharma V; Kwon E; Stish BJ; Davis BJ; Karnes RJ Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):514-523. PubMed ID: 33268854 [TBL] [Abstract][Full Text] [Related]
9. Safety and efficiency of repeat salvage lymph node dissection for recurrence of prostate cancer using PSMA-radioguided surgery (RGS) after prior salvage lymph node dissection with or without initial RGS support. Falkenbach F; Knipper S; Koehler D; Ambrosini F; Steuber T; Graefen M; Budäus L; Eiber M; Lunger L; Lischewski F; Heck MM; Maurer T World J Urol; 2023 Sep; 41(9):2343-2350. PubMed ID: 37515651 [TBL] [Abstract][Full Text] [Related]
10. Predictors of Recurrence After Metastasis-directed Therapy in Oligorecurrent Prostate Cancer Following Radical Prostatectomy. Milenkovic U; Kuijk J; Roussel E; Devos G; Van den Broeck T; Van Eecke H; Vanderstichele A; Duvillier T; Verhamme L; Van Haute W; Goeman L; Berghen C; Joniau S; De Meerleer G Eur Urol Oncol; 2023 Dec; 6(6):582-589. PubMed ID: 36878753 [TBL] [Abstract][Full Text] [Related]
11. Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer. Bravi CA; Heidenreich A; Fossati N; Gandaglia G; Suardi N; Mazzone E; Stabile A; Cucchiara V; Osmonov D; Juenemann KP; Karnes RJ; Kretschmer A; Buchner A; Stief C; Hiester A; Albers P; Devos G; Joniau S; Van Poppel H; Grubmüller B; Shariat S; Tilki D; Graefen M; Gill IS; Mottrie A; Karakiewicz PI; Montorsi F; Briganti A; Pfister D BJUI Compass; 2023 Jan; 4(1):123-129. PubMed ID: 36569505 [TBL] [Abstract][Full Text] [Related]